Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
120.30Today’s High
124.0052W low
81.2052W High
132.40Open Price
122.00Prev. Close
112.2000Volume
36025.00Value
4348217.50Fundamentals
Market Cap Cr
190.80
Price to Earnings
25.80
Price to Book Value
2.80
Dividend Yield
0.80
PE to Growth
0.10
Op Revenue TTM Cr
339.22
Net Profit TTM Cr
7.39
Cash From Operating Activity Cr
329.19
Return on Equity %
10.66
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
02 Jul, 2024
66.1
Week
65.3
Month
60.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
121.40
PIVOT
First Resistance
124.04
Second Resistance
126.49
Third Resistance
129.13
First Support
118.95
Second Support
116.31
Third Support
113.86
Relative Strength Index
63.65
Money Flow Index
57.05
MACD
3.06
MACD Signal
3.43
Average True Range
5.08
Average Directional Index
24.89
Rate of Change (21)
6.05
Rate of Change (125)
21.53
Commodity Channel Index
81.6
Williams %R
-37.9
BETA
1 Month
0.99
3 Month
0.63
1 Year
0.73
3 Year
0.28
PRICE CHANGE ANALYSIS
↑ 2%
1 Week
Low
High
116.01
123.99
↑ 5.28%
1 Month
Low
High
100
125.4
↑ 20.88%
3 Months
Low
High
95.15
131.9
↑ 15.95%
6 Months
Low
High
88.95
132.45
↑ 31.77%
1 Year
Low
High
81.2
132.45
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 96.81 | 81.75 | 92.71 | 70.61 | 82.41 | 77.34 | 75.44 | 70.07 | 77.70 | 70.10 | 67.91 | |
| Operating Expenses Qtr | 84.26 | 73.87 | 84.65 | 63.32 | 73.70 | 70.26 | 69.04 | 64.07 | 70.28 | 62.89 | 60.60 | |
| Operating Profit Qtr | 10.32 | 7.63 | 7.65 | 6.84 | 8.27 | 6.30 | 6.01 | 5.44 | 3.48 | 6.10 | 6.41 | |
| EBIDT Qtr Cr | 12.55 | 7.89 | 8.07 | 7.29 | 8.71 | 7.08 | 6.39 | 6.00 | 7.42 | 7.21 | 7.32 | |
| Depreciation Qtr | 1.76 | 2.55 | 2.02 | 2.12 | 1.66 | 2.03 | 1.96 | 1.83 | 2.11 | 1.71 | 1.72 | |
| Net Profit Qtr | 6.22 | 1.26 | 1.60 | 1.20 | 2.12 | 1.47 | 1.13 | 1.41 | 2.77 | 1.22 | 3.05 | |
| Basic EPS Qtr | 4.16 | 0.80 | 1.02 | 0.76 | 1.35 | 0.94 | 0.72 | 0.95 | 1.87 | 0.82 | 2.06 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 341.89 | 305.25 | 286.86 | 252.00 | 174.29 | |
| Operating Expenses Annual Cr | 306.10 | 277.07 | 257.16 | 222.99 | 163.92 | |
| Operating Profit Annual | 32.44 | 26.03 | 23.20 | 26.32 | 6.75 | |
| Operating Profit Margin Annual % | 9.49 | 8.53 | 8.09 | 10.44 | 3.87 | |
| Total Expenses Annual Cr | 329.79 | 296.70 | 274.80 | 242.20 | 183.36 | |
| EBIDT Annual Cr | 35.79 | 28.19 | 29.69 | 29.01 | 10.37 | |
| EBIDT Annual margin % | 10.47 | 9.23 | 10.35 | 11.51 | 5.95 | |
| Depreciation | 8.45 | 7.48 | 7.24 | 7.26 | 7.03 | |
| PAT Before ExtraOrdinary Items Annual Cr | 10.27 | 6.13 | 8.58 | 9.10 | -8.90 | |
| Net Profit Annual | 10.27 | 6.13 | 8.58 | 9.10 | -8.90 | |
| Basic EPS Annual | 6.72 | 3.90 | 5.79 | 6.41 | -6.28 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 105.58 | 96.03 | 87.32 | 79.32 | 65.94 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 46.56 | 39.52 | 37.72 | 35.35 | 33.42 | |
| Total Current Liabilities Annual Cr | 209.16 | 212.15 | 164.57 | 146.87 | 139.95 | |
| Total Capital Plus Liabilities Annual Cr | 361.30 | 347.70 | 289.61 | 261.54 | 239.31 | |
| Fixed Assets Annual | 65.03 | 63.07 | 54.06 | 52.65 | 56.24 | |
| Total Non Current Assets Annual | 80.16 | 77.75 | 69.35 | 68.34 | 66.84 | |
| Total Current Assets Annual | 281.14 | 269.95 | 220.27 | 193.20 | 172.47 | |
| Total Assets Annual | 361.30 | 347.70 | 289.61 | 261.54 | 239.31 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 16.44 | 16.25 | 4.34 | 12.99 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 33.35 | 5.07 | 31.48 | 10.24 | 21.57 | |
| Cash from Investing Activity Annual | 2.57 | -22.08 | -13.43 | -6.66 | -3.16 | |
| Cash from Financing Annual Activity | 24.21 | 17.43 | -18.13 | -3.36 | -19.94 | |
| Net Cash Flow Annual | - | 0.42 | -0.08 | 0.22 | -1.52 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 66.81 | 61.21 | 58.91 | 53.51 | 46.53 | |
| ROE Annual % | 9.72 | 6.37 | 9.82 | 11.46 | -13.49 | |
| ROCE Annual % | 17.97 | 15.27 | 17.95 | 18.97 | 3.36 | |
| Total Debt to Total Equity Annual | 1.27 | 1.30 | 1.12 | 1.25 | 1.42 | |
| EBDIT Annual Margin % | 10.57 | 9.29 | 10.59 | 11.63 | 6.07 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 97.08 | 81.76 | 92.68 | 70.54 | 82.64 | 77.08 | 75.36 | 70.08 | 77.75 | 69.92 | 67.73 | |
| Operating Expenses Qtr | 85.03 | 73.87 | 84.85 | 63.94 | 74.29 | 70.47 | 69.53 | 64.81 | 70.60 | 62.95 | 60.85 | |
| Operating Profit Qtr | 9.59 | 7.79 | 7.70 | 6.44 | 8.16 | 6.15 | 5.77 | 5.03 | 3.45 | 6.22 | 6.33 | |
| EBIDT Qtr Cr | 12.05 | 7.89 | 7.84 | 6.60 | 8.35 | 6.61 | 5.82 | 5.28 | 7.15 | 6.97 | 6.88 | |
| Depreciation Qtr | 2.16 | 2.96 | 2.42 | 2.53 | 2.09 | 2.45 | 2.37 | 2.23 | 2.42 | 2.21 | 2.21 | |
| Net Profit Qtr | 5.47 | 0.89 | 0.95 | 0.08 | 1.60 | 0.57 | 0.13 | 0.28 | 2.19 | 0.64 | 1.38 | |
| Basic EPS Qtr | 3.73 | 0.54 | 0.62 | 0.06 | 1.03 | 0.38 | 0.07 | 0.19 | 1.33 | 0.32 | 0.97 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 342.07 | 305.16 | 286.37 | 251.67 | 172.93 | |
| Operating Expenses Annual Cr | 307.69 | 279.09 | 257.74 | 226.07 | 166.33 | |
| Operating Profit Annual | 31.53 | 25.12 | 23.48 | 24.46 | 4.76 | |
| Operating Profit Margin Annual % | 9.22 | 8.23 | 8.20 | 9.72 | 2.75 | |
| Total Expenses Annual Cr | 333.02 | 300.41 | 277.18 | 247.56 | 186.46 | |
| EBIDT Annual Cr | 34.38 | 26.06 | 28.63 | 25.60 | 6.60 | |
| EBIDT Annual margin % | 10.05 | 8.54 | 10.00 | 10.17 | 3.82 | |
| Depreciation | 10.07 | 9.13 | 9.04 | 9.52 | 7.68 | |
| PAT Before ExtraOrdinary Items Annual Cr | 7.45 | 2.62 | 5.70 | 4.71 | -12.89 | |
| Net Profit Annual | 7.39 | 2.57 | 5.61 | 4.74 | -12.22 | |
| Basic EPS Annual | 4.94 | 1.67 | 3.79 | 3.34 | -9.10 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 69.29 | 63.79 | 58.63 | 53.58 | 52.43 | |
| Minority Interest Liability Annual Cr | -0.03 | -0.09 | -0.13 | -0.23 | -7.09 | |
| Total Non Current Liabilities Annual Cr | 47.22 | 40.14 | 36.40 | 34.19 | 33.56 | |
| Total Current Liabilities Annual Cr | 203.91 | 209.33 | 165.64 | 152.53 | 159.49 | |
| Total Capital Plus Liabilities Annual Cr | 320.39 | 313.17 | 260.53 | 240.08 | 238.39 | |
| Fixed Assets Annual | 73.46 | 72.64 | 65.18 | 64.76 | 70.20 | |
| Total Non Current Assets Annual | 85.38 | 85.02 | 75.96 | 75.93 | 77.26 | |
| Total Current Assets Annual | 235.01 | 228.16 | 184.57 | 164.15 | 161.14 | |
| Total Assets Annual | 320.39 | 313.17 | 260.53 | 240.08 | 238.39 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 0.00 | 0.00 | 4.34 | 12.99 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 329.19 | -1.84 | 27.71 | 21.78 | 23.10 | |
| Cash from Investing Activity Annual | 0.00 | -22.18 | -9.48 | -4.98 | -4.71 | |
| Cash from Financing Annual Activity | 34.58 | 24.40 | -18.13 | -16.63 | -19.97 | |
| Net Cash Flow Annual | - | 0.37 | 0.09 | 0.17 | -1.58 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 43.82 | 40.60 | 39.46 | 35.99 | 31.99 | |
| ROE Annual % | 10.66 | 4.03 | 9.57 | 8.85 | -23.30 | |
| ROCE Annual % | 20.86 | 16.30 | 20.64 | 18.36 | -1.36 | |
| Total Debt to Total Equity Annual | 2.02 | 2.05 | 1.67 | 1.95 | 2.15 | |
| EBDIT Annual Margin % | 10.13 | 8.56 | 10.18 | 10.21 | 3.85 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| SHAILESH SIROYA | 17.37 | 74518015 | 0 | 50.99 |
| ANITA SIROYA | 6.64 | 74518016 | 0 | 0 |
| ANAND SURANA | 3.33 | 74518017 | 0 | 0 |
| DILIP SURANA | 3.01 | 74518018 | 0 | 0 |
| ARCHANA SURANA | 1.8 | 74518019 | 0 | 0 |
| MONICA SURANA | 1.14 | 74518020 | 0 | 0 |
| DILIP SURANA (HUF) | 1.08 | 74518021 | 0 | 0 |
| MICRO LABS | 12.73 | 74518024 | 0 | 0 |
| CHANDRAPRAKASH DHEERAJMAL SIROYA | 3.08 | 74518026 | 0 | 0 |
| ANNITA CHANDRAPRAKASH SIROYA | 0.78 | 74518027 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| Naresh D.P | 1.9 | 74518038 |
| Shreya Mardia | 1.9 | 74518039 |
| HUF | 2.51 | 74518032 |
| Prakash Chandra Jain | 3.68 | 74518041 |
| Ram Keshav Murthy | 3.65 | 74518042 |
| Asha Tapidas Dodhia | 1.86 | 74518043 |
| Gautam Chand Mehta | 1.29 | 74518044 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Sep 18, 2023 | 1 | FINAL | - | Equity Share |
| Sep 13, 2022 | 1 | FINAL | - | Equity Share |
| Sep 16, 2021 | 1 | FINAL | - | Equity Share |
| Sep 17, 2019 | 1 | FINAL | - | Equity Share |
| Sep 14, 2018 | 1 | FINAL | - | Equity Share |
| Sep 14, 2017 | 1 | FINAL | - | Equity Share |
| Sep 15, 2016 | 1 | FINAL | - | Equity Share |
| Sep 15, 2015 | 1 | FINAL | - | Equity Share |
| Sep 12, 2014 | 1 | FINAL | - | Equity Share |
| Sep 12, 2013 | 0.75 | FINAL | - | Equity Share |
| Sep 17, 2009 | 0.75 | FINAL | - | Equity Share |
| Sep 09, 2008 | 1 | FINAL | - | Equity Share |
| Sep 07, 2007 | 0.75 | FINAL | - | Equity Share |
| Sep 07, 2006 | 0.75 | FINAL | - | Equity Share |
| Sep 09, 2005 | 0.75 | FINAL | - | Equity Share |
| Sep 01, 2004 | 1.5 | FINAL | - | Equity Share |
| Sep 11, 2002 | - | FINAL | - | Equity Share |
| Sep 03, 2001 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 28, 2024 | Audited Results & Final Dividend | - |
| Feb 12, 2024 | Quarterly Results | - |
| Nov 08, 2023 | Quarterly Results & ESOP | - |
| Aug 11, 2023 | Quarterly Results & A.G.M. | - |
| May 29, 2023 | Audited Results & Final Dividend | - |
| Feb 06, 2023 | Quarterly Results | - |
| Nov 14, 2022 | Quarterly Results & ESOP | Inter alia, To convene Extra Ordinary General Meeting ( EGM ) for merger of Golden Drugs Pvt Ltd. a wholly owned subsidiary of the Company. |
| Aug 11, 2022 | Quarterly Results | - |
| May 30, 2022 | Audited Results & Final Dividend | - |
| Apr 13, 2022 | Preferential issue of shares | - |
| Mar 09, 2022 | Scheme of Amalgamation | Inter alia consider approval of scheme of amalgamation between Bal Pharma Ltd and its wholly owned subsidiary i.e Golden Drugs Private Ltd. |
| Feb 10, 2022 | Quarterly Results | - |
| Nov 11, 2021 | Quarterly Results | - |
| Aug 10, 2021 | Quarterly Results | - |
| Jun 29, 2021 | Audited Results & Final Dividend | - |
| Mar 17, 2021 | Preferential Issue of shares | Inter alia, to consider and approve allotment of equity shares to the beneficiaries who have exercised the conversion option on the warrants allotted to them on preferential basis. |
| Feb 11, 2021 | Quarterly Results & Others | - |
| Nov 11, 2020 | Quarterly Results | - |
| Oct 28, 2020 | To consider issue of Warrants | To consider allotment of 14,00,000 warrants to Mr.Shailesh Siroya, promoter of the Company on preferential basis. |
| Sep 08, 2020 | Quarterly Results | - |
| Jul 29, 2020 | Audited Results & A.G.M. | - |
| Jun 29, 2020 | Audited Results | - |
| Feb 12, 2020 | Quarterly Results | - |
| Nov 14, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results | (Revised) |
| Aug 08, 2019 | Quarterly Results | - |
| May 30, 2019 | Audited Results & Final Dividend | (Revised) |
| May 29, 2019 | Audited Results & Final Dividend | - |
| Feb 13, 2019 | Quarterly Results | - |
| Nov 14, 2018 | Quarterly Results | - |
| Aug 10, 2018 | Quarterly Results | - |
| May 29, 2018 | Audited Results & Dividend | - |
| Feb 14, 2018 | Quarterly Results | - |
| Dec 11, 2017 | Quarterly Results | - |
| Sep 11, 2017 | Quarterly Results | - |
| Aug 10, 2017 | Others | To approve the 30th Annual General Meeting Notice (AGM), Directors Report and Corporate Governance reports of the Company, for the financial year ended 31.03.2017. |
| May 30, 2017 | Audited Results & Dividend | - |
| Feb 07, 2017 | Quarterly Results | - |
| Nov 14, 2016 | Quarterly Results | - |
| Aug 10, 2016 | Quarterly Results | To consider certain key business propositions. |
| May 25, 2016 | Audited Results & Dividend | - |
| Apr 13, 2016 | Allotment of Equity Shares | - |
| Feb 10, 2016 | Quarterly Results | - |
| Nov 09, 2015 | Quarterly Results | - |
| Aug 13, 2015 | Quarterly Results | Appointed Mr. Sanjay Kumar Agarwal as Company Secretary and Compliance officer of the Company. |
| May 29, 2015 | Audited Results & Dividend | - |
| Mar 27, 2015 | Others | Appointed Ms.Sarika Bhandari as additional Director on the Board of the Company. |
| Feb 12, 2015 | Quarterly Results | - |
| Nov 08, 2014 | Quarterly Results | - |
| Oct 20, 2014 | Others | To consider issue and allotment of warrants to the investors on preferential basis. |
| Aug 11, 2014 | Quarterly Results & Others | Preferential Issue of shares |
| May 28, 2014 | Audited Results & Dividend | - |
| Feb 12, 2014 | Quarterly Results | - |
| Nov 13, 2013 | Quarterly Results | - |
| Aug 12, 2013 | Quarterly Results | - |
| May 27, 2013 | Audited Results & Dividend | - |
| Feb 12, 2013 | Quarterly Results | - |
| Nov 09, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Audited & Quarterly Results | 1. Propose issue and allotment of warrants on preferential basis to the promoters and to strategic investors. 2. Approve the audited accounts of the Company for the F.Y. ended March 31, 2012. |
| May 10, 2012 | Quarterly Results | - |
| Feb 03, 2012 | Quarterly Results | - |
| Nov 08, 2011 | Quarterly Results | - |
| Aug 10, 2011 | Audited & Quarterly Results | - |
| May 15, 2011 | Quarterly Results | (Revised) |
| Jan 31, 2011 | Quarterly Results | - |
| Nov 13, 2010 | Quarterly Results | - |
| Aug 06, 2010 | Audited & Quarterly Results | - |
| May 14, 2010 | Quarterly Results | - |
| Jan 27, 2010 | Quarterly Results | - |
| Oct 31, 2009 | Quarterly Results | - |
| Jul 27, 2009 | Quarterly Results | - |
| Jun 29, 2009 | Audited Results & Dividend | - |
| May 28, 2009 | Scheme of Amalgamation | To consider & approve the draft Scheme of Amalgamation of Basav Chem Ltd. (100% subsidiary Company) , with the Company in terms of Sections 391 to 394 of the Companies Act, 1956. |
| Jan 30, 2009 | Quarterly Results | - |
| Oct 27, 2008 | Quarterly Results & Others | To allot 37,000 equity shares of face value @ Rs 10/- each, allotted at Rs 15.75/- per equity share to the eligible employees of the Company under ESOP Scheme, 2006. |
| Jul 30, 2008 | Quarterly Results | - |
| Jun 23, 2008 | Audited Results & Dividend | - |
| Apr 16, 2008 | Others | Inter alia, to take on record the sales performance of the Company, up to March 31, 2008. |
| Jan 24, 2008 | Quarterly Results | - |
| Oct 30, 2007 | Quarterly Results | - |
| Jul 30, 2007 | Quarterly Results | - |
| Jun 30, 2007 | Audited Results | - |
| Jan 31, 2007 | Quarterly Results | - |
| Oct 27, 2006 | Quarterly Results | - |
| Jul 31, 2006 | Quarterly Results | - |
| Jun 30, 2006 | Accounts | - |
| Apr 30, 2006 | Quarterly Results | - |
| Jan 30, 2006 | Quarterly Results | - |
| Oct 29, 2005 | Quarterly Results | - |
| Jul 30, 2005 | Quarterly Results | - |
| Jun 30, 2005 | Accounts & Dividend | - |
| May 31, 2005 | Others | To review of the response of the shareholders with regard to Right Issue |
| Jan 31, 2005 | Quarterly Results | - |
| Dec 26, 2004 | Right Issue of Equity Shares | & To obtain share holders approval by postal ballot to amend object clause of the MOA. |
| Oct 31, 2004 | Quarterly Results | - |
| Oct 07, 2004 | Preferential Issue of shares | 1) Allotment of 10,30,000 shares on preferential basis and 2) Redemption of preference shares. |
| Jul 31, 2004 | Others | Approved allotment of Equity shares on Preferential basis |
| Apr 30, 2004 | Quarterly Results | - |
| Jan 30, 2004 | Quarterly Results | - |
| Oct 23, 2003 | Quarterly Results | - |
| Jul 28, 2003 | Quarterly Results | (Revised) |
| Jul 14, 2003 | Accounts & Dividend | - |
| Apr 26, 2003 | Quarterly Results | - |
| Jan 30, 2003 | Quarterly Results | (Revised) |
| Oct 29, 2002 | Quarterly Results | - |
| Jul 15, 2002 | Accounts, Dividend & Quarterly Results | - |
| Apr 30, 2002 | Quarterly Results | - |
| Jan 30, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Accounts & Quarterly Results | - |
| Jan 30, 2001 | Quarterly Results | - |
| Oct 28, 2000 | Quarterly Results | - |
| Jul 28, 2000 | Quarterly Results | - |
| Apr 28, 2000 | Quarterly Results | - |
| Jan 28, 2000 | Quarterly Results | - |
| Oct 27, 1999 | Quarterly Results | - |
| Jul 30, 1999 | Quarterly Results | - |
| Apr 29, 1999 | Quarterly Results | - |
| Mar 06, 1999 | Pvt. Placements | - |
| Jan 29, 1999 | Quarterly Results | - |
| Oct 26, 1998 | Quarterly Results | - |
| May 30, 1998 | Half Yearly Results | - |
| Nov 28, 1997 | Half Yearly Results. | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
28 Jun 2024
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Change in Directorate
We would like to inform the exchanges that Dr.C.V Srinivas ( DIN# 04495304) Independent Director of the Company has completed his tenure of five years as Independent Director of the Company and he ceases to be on the Board of the Company w.e.f 28.06.2024.
25 Jun 2024
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Trading Window of the Company on designated persons and their immediate relatives will be closed from 1st July 2024 until 48 hours of declaration of the Un Audited financial results for the quarter ended 30.06.2024.
03 Jun 2024
BAL PHARMA LTD. - 524824 - Disclosure under Regulation 30A of LODR
Disclosure as per Regulation 31 A of SEBI (LODR) Regulations- Intimation reg receipt of applications from promoters for reclassification of their shareholding in the Company as Public holding.
30 May 2024
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance with Regulation 47 of SEBI(LODR) Regulations, we are submitting the newspaper advertisements of the abridged Audited standalone and consolidated financial results of the company for the quarter and year ended 31.03.2024 announced by the Company on 28.05.2024 and published in Financial Express ( English) and Snajayvani ( Kannada ) on 29.05.2024.
29 May 2024
BAL PHARMA LTD. - 524824 - Corporate Action-Board approves Dividend
Board of Directors of the Company at their meeting held on 28.05.2024 has recommended payment of Dividend of Re.1.20 paise per equity share of Rs.10 each i.e 12%, which is subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting .
28 May 2024
BAL PHARMA LTD. - 524824 - Audited Financial Results 31.03.2024
Audited stand alone & Consolidated financial results for the quarter and financial year ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.
28 May 2024
BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
Board of Directors of the Company has met today and inter alia transacted the following business, 1.Approved the audited financial results ( Stand alone & Consolidated ) for the quarter and financial year ended 31.03.2024. Copies of the approved financial results along with Declaration of Unmodified opinion and Audit reports issued by the statutory auditors are enclosed for submitting to the exchanges. 2. Recommended a Dividend of Rs.1.20 per equity share of Rs.10 each i.e 12% which is subject to the approval of shareholders at the ensuing AGM. 2. Reappointed Mr.M.R Krishna Murthy, Cost Accountant as Cost Auditor , M/s Murugesh & Co, Chartered Accountants as Internal auditors and Mr.Parameshwar Bhat, PCS as Secretarial Auditors of the Company for the F.Y 2024-25.
27 May 2024
BAL PHARMA LTD. - 524824 - Compliances-Reg.24(A)-Annual Secretarial Compliance
We are submitting the Annual Secretarial Compliance report duly certificated by the practicing Company Secretary for the financial year ended 31.03.2024.
21 May 2024
BAL PHARMA LTD. - 524824 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation reg loss of Share Certificate
03 May 2024
BAL PHARMA LTD. - 524824 - Corporate Action-Board to consider Dividend
Please refer to our intimation regarding Board Meeting dated 30.04.2024.
